Condition: Renal Cell Carcinoma Metastatic · Prostate Cancer Metastatic · Non-small Cell Lung Cancer Metastatic · Sponsor: Kidney Cancer Research Bureau
One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family. The goal of this clinical trial is to learn if monoclonal anti-FGFR1 antibody (OM-RCA-01) works to treat metastatic cancers expressing FGFR1. It will also learn about the safety of drug OM-RCA-01. The main questions it aims to answer are: 1. What medical problems do participants have when receiving drug OM-RCA-01? 2. What dose of the drug should patients receive in the next studies? 3. Does tumor growth slow down in patients receiving OM-RCA-01? All patients in this study will receive the antibody treatment. The drug will be given through a vein (by IV infusion) every two weeks, for as long as the disease remains under control and the treatment is well tolerated.
This description comes directly from the study's public registry record.
Ilya Tsimafeyeu, MD, PhD · 9178914943 · sten_to@mail.ru
Always discuss trial participation with your own doctor first.
| Republican Dispensary of Tatarstan | Kazan', Russia | Active Not Recruiting |
| A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center | Krasnoyarsk, Russia | Recruiting |
| Hadassah Medical | Moscow, Russia | Recruiting |
| I.P. Pavlov First Saint Petersburg State Medical University | Saint Petersburg, Russia | Recruiting |
| Republican Clinical Oncology Dispensary | Ufa, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07292168